TGTX
NEUTRAL
$36.96
Live
TG Therapeutics, Inc. · NASDAQ
Target $44.57
(+20.6%)
$25.28
52W Range
$46.48
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 21, 2026
Market cap
$5.9B
P/E
13.34
ROE
102.8%
Profit margin
72.6%
Debt/Equity
0.39
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
TGTX exhibits a stable financial foundation with a Piotroski F-Score of 6/9 and exceptional profitability margins, yet it faces a significant valuation gap. The stock is trading at $36.96, which is nearly double its Graham Number ($16.79) and Intrinsic Value ($19.39). While revenue growth is explosive at 78%, the company has missed earnings estimates in four consecutive quarters with an average surprise of -41.54%, and YoY earnings growth has turned negative (-6.10%). The disconnect between strong top-line growth and failing bottom-line expectations creates a high-risk profile despite the 'Buy' analyst consensus.
Key Strengths
Exceptional profit margins (72.56%) and gross margins (83.66%)
Strong liquidity with a Current Ratio of 4.10 and Quick Ratio of 2.91
Explosive YoY revenue growth of 78.00%
Very high Return on Equity (ROE) of 102.75%
Low leverage with a Debt/Equity ratio of 0.39
Key Risks
Severe valuation premium over Graham and Intrinsic value baselines
Consistent earnings misses (0/4 beats in the last 4 quarters)
Negative YoY earnings growth (-6.10%) despite revenue surge
Bearish technical trend (0/100) and weak insider sentiment (30/100)
High Price/Book (8.17) and Price/Sales (9.58) ratios
AI Fair Value Estimate
Based on comprehensive analysis
$21.5
-41.8% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
46
Moderate
30
60
55
85
0
AI Verdict
Speculative Growth
Key drivers: High revenue growth, Extreme profitability margins, Consistent earnings misses, Significant overvaluation relative to deterministic models
Confidence
90%
Value
30/100
Ref P/E 13.34, PEG 1.61, Graham Number $16.79
Positives
- P/E of 13.34 is relatively low for the biotech sector
Watchpoints
- Price is ~120% above Graham Number
- Price is ~91% above Intrinsic Value
- High P/S and P/B ratios
Future
60/100
Ref Revenue Growth 78% vs Earnings Growth -6.10%
Positives
- Strong 78% revenue growth
Watchpoints
- Negative earnings growth
- Failure to meet analyst EPS expectations
Past
55/100
Ref Quarterly Earnings Progression
Positives
- Successful transition to profitability
Watchpoints
- Poor earnings surprise track record (-41.54% avg last 4 quarters)
Health
85/100
Ref Piotroski F-Score 6/9, Debt/Equity 0.39
Positives
- Piotroski F-Score 6/9 (Stable)
- Low Debt/Equity
- High Current Ratio
Watchpoints
- Altman Z-Score not provided
Dividend
0/100
Ref Dividend Yield N/A
Positives
No standout positives identified.
Watchpoints
- No dividend payments
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$36.96
Analyst Target
$44.57
Upside/Downside
+20.6%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for TGTX and closest competitors.
Updated 2026-04-20
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
TGTX
TG Therapeutics, Inc.
Primary
|
-9.2% | +66.9% | -0.0% | +5.2% | +22.9% | +9.4% |
|
MIRM
Mirum Pharmaceuticals, Inc.
Peer
|
+417.6% | +286.1% | +143.7% | +33.7% | +6.4% | +0.3% |
|
PTCT
PTC Therapeutics, Inc.
Peer
|
+52.4% | +36.8% | +52.8% | +9.8% | +8.1% | +5.4% |
|
BLCO
Bausch + Lomb Corporation
Peer
|
-15.1% | -0.2% | +0.8% | +18.6% | -0.2% | -1.1% |
|
RYTM
Rhythm Pharmaceuticals, Inc.
Peer
|
+337.8% | +324.8% | +43.6% | -19.6% | +3.3% | +5.1% |
TGT
TG Therapeutics, Inc.
Primary
5Y
-9.2%
3Y
+66.9%
1Y
-0.0%
6M
+5.2%
1M
+22.9%
1W
+9.4%
MIR
Mirum Pharmaceuticals, Inc.
Peer
5Y
+417.6%
3Y
+286.1%
1Y
+143.7%
6M
+33.7%
1M
+6.4%
1W
+0.3%
PTC
PTC Therapeutics, Inc.
Peer
5Y
+52.4%
3Y
+36.8%
1Y
+52.8%
6M
+9.8%
1M
+8.1%
1W
+5.4%
BLC
Bausch + Lomb Corporation
Peer
5Y
-15.1%
3Y
-0.2%
1Y
+0.8%
6M
+18.6%
1M
-0.2%
1W
-1.1%
RYT
Rhythm Pharmaceuticals, Inc.
Peer
5Y
+337.8%
3Y
+324.8%
1Y
+43.6%
6M
-19.6%
1M
+3.3%
1W
+5.1%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
13.34
Forward P/E
15.01
PEG Ratio
1.61
P/B Ratio
8.17
P/S Ratio
9.58
EV/Revenue
9.04
EV/EBITDA
45.15
Market Cap
$5.9B
Profitability
Profit margins and return metrics
Profit Margin
72.56%
Operating Margin
26.22%
Gross Margin
83.66%
ROE
102.75%
ROA
9.39%
Growth
Revenue and earnings growth rates
Revenue Growth
+78.0%
Earnings Growth
-6.1%
Q/Q Revenue Growth
+78.0%
Q/Q Earnings Growth
-1.3%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.39
Low debt
Current Ratio
4.1
Strong
Quick Ratio
2.91
Excellent
Cash/Share
$0.96
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.2B
Gross Margin
80.2%
Op. Margin
26.2%
Net Margin
12.0%
Total Assets
$1.1B
Liabilities
$0.4B
Equity
$0.6B
Debt/Equity
0.64x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
100%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-04
$N/A
2026-02-26
$0.14
-57.5% surprise
2025-11-03
$0.16
-26.3% surprise
2025-08-04
$0.17
-40.9% surprise
Healthcare Sector Comparison
Comparing TGTX against 498 companies in the Healthcare sector
(28 bullish, 153 neutral, 317 bearish)
P/E Ratio
13.34
This Stock
vs
84.2
Sector Avg
-84.2%
(Discount)
Return on Equity (ROE)
102.75%
This Stock
vs
-95.47%
Sector Avg
-207.6%
(Below Avg)
Profit Margin
72.56%
This Stock
vs
-15.87%
Sector Avg
-557.2%
(Weaker)
Debt to Equity
0.39
This Stock
vs
2.89
Sector Avg
-86.4%
(Less Debt)
Revenue Growth
78.0%
This Stock
vs
137.48%
Sector Avg
-43.3%
(Slower)
Current Ratio
4.1
This Stock
vs
4.66
Sector Avg
-12.0%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
TGTX
TG Therapeutics, Inc.
|
NEUTRAL | $5.9B | 13.34 | 102.8% | 72.6% | $36.96 | |
|
MIRM
Mirum Pharmaceuticals, Inc.
|
BEARISH | $5.82B | - | -8.6% | -4.5% | $96.49 | Compare |
|
PTCT
PTC Therapeutics, Inc.
|
NEUTRAL | $6.0B | 8.44 | -% | 39.4% | $72.43 | Compare |
|
BLCO
Bausch + Lomb Corporation
|
BEARISH | $6.01B | - | -4.5% | -6.1% | $16.98 | Compare |
|
RYTM
Rhythm Pharmaceuticals, Inc.
|
NEUTRAL | $6.06B | - | -90.5% | -103.6% | $88.69 | Compare |
TGTX
TG Therapeutics, Inc.
NEUTRAL
Mkt Cap
$5.9B
P/E
13.3
ROE
102.8%
Price
$36.96
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-29 | CHARNEY LAURENCE NEIL | Director | Gift | 43,197 | - |
| 2026-01-08 | WEISS MICHAEL S | Chief Executive Officer | Stock Award | 622,000 | - |
| 2026-01-08 | POWER SEAN A | Chief Financial Officer | Stock Award | 90,000 | - |
| 2025-11-24 | ECHELARD YANN | Director | Sale | 5,000 | $162,850 |
| 2025-11-05 | WEISS MICHAEL S | Chief Executive Officer | Gift | 4,668,843 | - |
CHARNEY LAURENCE NEIL
Director
2026-01-29
43,197 shares
WEISS MICHAEL S
Chief Executive Officer
2026-01-08
622,000 shares
POWER SEAN A
Chief Financial Officer
2026-01-08
90,000 shares
ECHELARD YANN
Director
2025-11-24
5,000 shares
·
$162,850
WEISS MICHAEL S
Chief Executive Officer
2025-11-05
4,668,843 shares
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
10-K
8-K
10-Q
8-K
10-Q
8-K
10-Q
Data sourced from SEC EDGAR. AI summaries generated automatically.
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
7 analysts
JP Morgan
2026-02-02
Overweight
Overweight
Goldman Sachs
2026-01-15
Neutral
Neutral
JP Morgan
2025-11-03
Overweight
Overweight
Past News Coverage
Recent headlines mentioning TGTX from our newsroom.
Newest → oldest
No matching news yet.